All News
Update on Polymyalgia Rheumatica and Giant Cell Arteritis (Best of 2020)
JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has approved tocilizumab as a first-line glucocorticoid-sparing agent.
Read Article
The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis
Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.
Read Article
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
#BestACR20Tweets
RT @RichardPAConway : Really important study by @SattuiSEMD on high prevalence of frailty and its impact on QOL in PMR #ACR20 @rheumnow Abstr#422 https://t.co/QzDYGsqDeJ
Dr. John Cush RheumNow ( View Tweet)
Check out our latest article from Richard Conway ( @RichardPAConway) #ACR20
The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis
https://t.co/VG1ah3Nq5c https://t.co/js3l527VHg
Links:
Dr. John Cush RheumNow ( View Tweet)
Imaging and Large Vessel Vasculitis: Dr. Alexa S. Meara interviews Dr. Kaitlin Quinn #ACR20
https://t.co/CWN2C1P6Fz https://t.co/yHg63VPkiW
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RHEUMarampa : Novel predictors of early mortality in a cohort of GCA pts from Portugal:
🚩Older age at dx
🚩Tongue claudication
🚩Prior tx w/ anticoag
BP treatment at dx - predictor of early survival. @RheumNow #ACR20 abs1935 https://t.co/vCi2gMCmKE https://t.co/HuTv1p8Yua
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway :Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @DrPujaMehta1 #ACR20 Abstr#L06 https://t.co/ynWbguXXzR
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @SattuiSEMD :L06: Mavrilimumab in #GCA
Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new/relapsing/ref pts, No diff in AE
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
Disease flare 19% in tx vs. 46% in PBO at 26wk
Sustained remission 83% vs. 50% in PBO
Similar AE in both groups Abs#L06
https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna: #ACR20 prosp cohort study of angiographic lesions in Takayasu’ GCA:new angio lesions more likely in TAK.Improvement possible in both conditions, more likely in TAK.Change in the branch arteries more dynamic than in the aorta https://t.co/iC0TJ08Tsr https://t.co/Y1hIDGJ9Ro
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : @RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/M97X8fLfLp
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestARC20Tweets
"RT @drdavidliew : Great to sit down with @LCalabreseDO @Sarah_L_Mackie @RichardPAConway a few hours ago and chat about two very interesting GCA therapeutics abstracts: https://t.co/V3fzB0W3Ko
great discussion!
#ACR20 @RheumNow"
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/Ay7Sw0eMTY
Links:
Dr. John Cush RheumNow ( View Tweet)
"The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis" by Dr. Richard Conway ( @RichardPAConway)
https://t.co/VG1ah3Nq5c https://t.co/jORhfQn3EC
Links:
Dr. John Cush RheumNow ( View Tweet)
Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh #ACR20
https://t.co/kJxdgoL5EI https://t.co/uYUwUr53lL
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/HrMGvqcNC4
Links:
Dr. John Cush RheumNow ( View Tweet)
San Diego-based rheumatologist Dr. Arthur Kavanaugh takes a closer look at Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis #ACR20.
https://t.co/53gQ0dLjU7
Links:
Dr. John Cush RheumNow ( View Tweet)
Evolution of GCA Treatments - More to Come by Meral El Ramahi ( @MeralElRamahiMD) #ACR20
Reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA)
https://t.co/xuQ7Litn8t https://t.co/4NtVSMOPsS
Links:
Dr. John Cush RheumNow ( View Tweet)
